The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Pilarski, Robert ^a   Patel, Divya A ^b   Weitzel, Jeffrey ^c   McVeigh, Terri ^d   Dorairaj, Jemima J ^d   Heneghan, Helen M ^d   Miller, Nicola ^d   Weidhaas, Joanne B ^b   Kerin, Michael J ^d   McKenna, Megan ^e   Wu, Xifeng ^f   Hildebrandt, Michelle ^f   Zelterman, Daniel ^g   Sand, Sharon ^c   Shulman, Lee P ^h  

^a OHIO STATE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Division of Clinical Cancer Genetics   (United States)

^d NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^e Cancer Center of Santa Barbara   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g YALE UNIVERSITY   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER DIAGNOSIS; CANCER RISK; CARCINOGENESIS; CAUCASIAN; CONTROLLED STUDY; DOUBLE PRIMARY PATIENT; ETHNIC DIFFERENCE; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GERM LINE; HISPANIC; HUMAN; KRAS VARIANT; MAJOR CLINICAL STUDY; MULTIPLE CANCER; ONCOGENE; ONSET AGE; OVARY CANCER; OVARY CARCINOGENESIS; PATIENT; PATIENT INFORMATION; PATIENT REFERRAL; POSTMENOPAUSE; PREDICTION; PREMENOPAUSE; PREVALENCE; VALIDATION STUDY;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, RAS; GENETIC VARIATION; HUMANS; MIDDLE AGED; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; OVARIAN NEOPLASMS; PREVALENCE; RISK;

EID: 84861463747     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037891     Document Type: Article

References (17)

1. Antoniou A, Pharoah P, Narod S, Risch H, Eyfjord J, et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117-1130.
2. Ford D, Easton D, Stratton M, Narod S, Goldgar D, et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676-689.
3. Fishman A, Dekel E, Chetrit A, Lerner-Geva L, Bar-Am A, et al. (2000) Patients with double primary tumors in the breast and ovary-clinical characteristics and BRCA1-2 mutations status. Gynecol Oncol 79: 74-78.
4. Evans D, Ahmed M, Bayliss S, Howard E, Lalloo F, et al. (2010) BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasta and/or ovaries. J Med Genet 47: 561-566.
5. Cvelbar M, Hocevar M, Vidmar G, Teugels E, (2011) BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer. Neoplasma 58: 198-204.
6. Armstrong K, Calzone K, Stopfer J, Fitzgerald G, Coyne J, et al. (2000) Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 9: 1251-1254.
7. Stadler Z, Kauff N, (2010) Weighing options for cancer risk reduction in carriers of BRCA1 and BRCA2 mutations. J Clin Oncol 28: 189-191.
8. Metcalfe K, Finch A, Poll A, Horsman D, Kim-Sing C, et al. (2009) Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br J Cancer 100: 421-425.
9. Ratner E, Lu L, Boeke M, Barnett R, Nallur S, et al. (2010) A KRAS-variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research 15: 6509-6515.
10. Paranjape T, Heneghan H, Lindner R, Keane F, Hoffman A, et al. (2011) A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncology.
11. Chin L, Ratner E, Leng S, Zhai R, Nullur S, et al. (2008) A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res 68: 8535-8540.
12. Christensen B, Moyer B, Avissar M, Ouellet L, Plaza S, et al. (2009) A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associatied with reduced survival in oral cancers. Carcinogenesis 30: 1003-1007.
13. Pharoah P, Palmieri R, Ramus S, Gayther S, Andrulis I, et al. (2011) The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res online March 8th.
14. Ratner E, Keane F, Lindner R, Tassi R, Paranjape T, et al. (2011) A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistance and a Potential Target for Therapy in Ovarian Cancer. Oncogene Dec 5.
15. Chan E, Patel R, Nallur S, Bacchiocchi A, Hoyt K, et al. (2011) MicroRNA signatures differentiate melanoma subtypes. Cell Cycle 10 epub ahead of print.
16. Walsh T, Casadei S, Coats K, Swisher E, Stray S, et al. (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295: 1379-1388.
17. Palma M, Domchek S, Stopfer J, Erlichman J, Siegfried J, et al. (2008) The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res 68: 7006-7014.